SCOPUS 정보 검색 플랫폼

mAbs

Volumn 1, Issue 5, 2009, Pages 439-442

Motavizumab

(1) Cingoz, Oya a

a TUFTS UNIVERSITY SCHOOL OF MEDICINE (United States)

Author keywords

MEDI 524; Motavizumab; Numax; Respiratory syncytial virus (RSV)

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; MEDI 524 MONOCLONAL ANTIBODY, HUMAN; MEDI-524 MONOCLONAL ANTIBODY, HUMAN; MONOCLONAL ANTIBODY;

CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEMODYNAMICS; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INCIDENCE; NONHUMAN; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS LOAD; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TREATMENT OUTCOME;

EID: 77950355484 PISSN: 19420862 EISSN: None Source Type: Journal
DOI: 10.4161/mabs.1.5.9496 Document Type: Short Survey

Times cited : (24)

References (12)

1
- 38449102652
- Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab
- Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-123
- (2008) Curr Top Microbiol Immunol , vol.317 , pp. 103-123
- Wu, H.¹ Pfarr, D.S.² Losonsky, G.A.³ Kiener, P.A.⁴

2
- 0020535923
- Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study
- Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308:1443-1447
- (1983) N Engl J Med , vol.308 , pp. 1443-1447
- Hall, C.B.¹ McBride, J.T.² Walsh, E.E.³ Bell, D.M.⁴ Gala, C.L.⁵ Hildreth, S.⁶

3
- 38449102652
- Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab
- Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-123
- (2008) Curr Top Microbiol Immunol , vol.317 , pp. 103-123
- Wu, H.¹ Pfarr, D.S.² Losonsky, G.A.³ Kiener, P.A.⁴

4
- 16944363559
- Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
- Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-1224 (Pubitemid 27460986)
- (1997) Journal of Infectious Diseases , vol.176 , Issue.5 , pp. 1215-1224
- Johnson, S.¹ Oliver, C.² Prince, G.A.³ Hemming, V.G.⁴ Pfarr, D.S.⁵ Wang, S.-C.⁶ Dormitzcr, M.⁷ O'Grady, J.⁸ Koenig, S.⁹ Tamura, J.K.¹⁰ Woods, R.¹¹ Bansal, G.¹² Couchenour, D.¹³ Tsao, E.¹⁴ Hall, W.C.¹⁵ Young, J.F.¹⁶

5
- 63849263058
- Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations
- Weisman LE. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr Opin Mol Ther 2009; 2:208-218
- (2009) Curr Opin Mol Ther , vol.2 , pp. 208-218
- Weisman, L.E.¹

6
- 27644485407
- Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus Potency
- DOI 10.1128/AAC.49.11.4700-4707.2005
- Mejías A, Chávez-Bueno S, Ríos AM, Aten MF, Raynor B, Peromingo E, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700-4707 (Pubitemid 41552602)
- (2005) Antimicrobial Agents and Chemotherapy , vol.49 , Issue.11 , pp. 4700-4707
- Mejias, A.¹ Chavez-Bueno, S.² Rios, A.M.³ Aten, M.F.⁴ Raynor, B.⁵ Peromingo, E.⁶ Soni, P.⁷ Olsen, K.D.⁸ Kiener, P.A.⁹ Gomez, A.M.¹⁰ Jafri, H.S.¹¹ Ramilo, O.¹²

7
- 20444363121
- Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization
- DOI 10.1016/j.jmb.2005.04.049, PII S0022283605004833
- Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005; 350:126-144 (Pubitemid 40804737)
- (2005) Journal of Molecular Biology , vol.350 , Issue.1 , pp. 126-144
- Wu, H.¹ Pfarr, D.S.² Tang, Y.³ An, L.-L.⁴ Patel, N.K.⁵ Watkins, J.D.⁶ Huse, W.D.⁷ Kiener, P.A.⁸ Young, J.F.⁹

8
- 34047143155
- Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract
- DOI 10.1016/j.jmb.2007.02.024, PII S0022283607002057
- Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-665 (Pubitemid 46527610)
- (2007) Journal of Molecular Biology , vol.368 , Issue.3 , pp. 652-665
- Wu, H.¹ Pfarr, D.S.² Johnson, S.³ Brewah, Y.A.⁴ Woods, R.M.⁵ Patel, N.K.⁶ White, W.I.⁷ Young, J.F.⁸ Kiener, P.A.⁹

9
- 77953661769
- Safety and efficacy of motavizumab in the prevention of RSV disease in healthy infants
- Chandran A, Millar EV, Weatherholtz R, Campbell JJ, Perilla MJ, Moulton LH, et al. Safety and efficacy of motavizumab in the prevention of RSV disease in healthy infants. Pediatric Academic Societies Annual Meeting Abstracts 2008; 4460-4465
- Pediatric Academic Societies Annual Meeting Abstracts 2008 , pp. 4460-4465
- Chandran, A.¹ Millar, E.V.² Weatherholtz, R.³ Campbell, J.J.⁴ Perilla, M.J.⁵ Moulton, L.H.⁶

10
- 70349555015
- Phase III trial of motavizumab, an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody for the prevention of serious RSV disease in high risk infants
- Simoes E, Carbonell X, Losonsky G, Hultquist M, Harris B, Connor E. Phase III trial of motavizumab, an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody for the prevention of serious RSV disease in high risk infants. Acta Paediatrica 2007; 96:232-233
- (2007) Acta Paediatrica , vol.96 , pp. 232-233
- Simoes, E.¹ Carbonell, X.² Losonsky, G.³ Hultquist, M.⁴ Harris, B.⁵ Connor, E.⁶

11
- 79952748764
- Phase 1/2 trial in high risk infants of Medi-524 (Numax TM), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody
- Losonsky G, Fernandez P, Abarca K, Jung E, Gerdes J, Hultquist M, et al. Phase 1/2 trial in high risk infants of Medi-524 (Numax TM), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody. Pediatric Academic Societies Annual Meeting Abstracts 2005.
- Pediatric Academic Societies Annual Meeting Abstracts 2005
- Losonsky, G.¹ Fernandez, P.² Abarca, K.³ Jung, E.⁴ Gerdes, J.⁵ Hultquist, M.⁶

12
- 65649105815
- Safety, tolerability, pharmacokinetics and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children
- Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, et al. Safety, tolerability, pharmacokinetics and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009; 28:267-272
- (2009) Pediatr Infect Dis J , vol.28 , pp. 267-272
- Abarca, K.¹ Jung, E.² Fernández, P.³ Zhao, L.⁴ Harris, B.⁵ Connor, E.M.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.